|
1
|
Kaufman AJ and Pass HI: Current concepts
in malignant pleural mesothelioma. Expert Rev Anticancer Ther.
8:293–303. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hansen J, de Klerk NH, Musk AW and Hobbs
MS: Environmental exposure to crocidolite and mesothelioma:
exposure-response relationships. Am J Respir Crit Care Med.
157:69–75. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Robinson BWS and Lake RA: Advances in
malignant mesothelioma. N Engl J Med. 353:1591–1603. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sugarbaker DJ, Flores RM, Jaklitsch MT, et
al: Resection margins, extrapleural nodal status, and cell type
determine postoperative long-term survival in trimodality therapy
of malignant pleural mesothelioma: results in 183 patients. J
Thorac Cardiovasc Surg. 117:54–63. 1999. View Article : Google Scholar
|
|
5
|
Vogelzang NJ, Rusthoven JJ, Symanowski J,
et al: Phase III study of PEM in combination with cisplatin versus
cisplatin alone in patients with malignant pleural mesothelioma. J
Clin Oncol. 21:2636–2644. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hurwitz JL, Stasik I, Kerr EM, et al:
Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is
FLIP/caspase 8-dependent and HR23B-independent. Eur J Cancer.
48:1096–1107. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vandermeers F, Hubert P, Delvenne P, et
al: Valproate, in combination with pemetrexed and cisplatin,
provides additional efficacy to the treatment of malignant
mesothelioma. Clin Cancer Res. 15:2818–2828. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ramalingam SS, Parise RA, Ramanathan RK,
et al: Phase I and pharmacokinetic study of vorinostat, a histone
deacetylase inhibitor, in combination with carboplatin and
paclitaxel for advanced solid malignancies. Clin Cancer Res.
13:3605–3610. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zitvogel L, Tesniere A and Kroemer G:
Cancer despite immunosurveillance: immunoselection and
immunosubversion. Nat Rev Immunol. 6:715–727. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zou W: Immunosuppressive networks in the
tumour environment and their therapeutic relevance. Nat Rev Cancer.
5:263–274. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Seike M, Yanaihara N, Bowman ED, et al:
Use of a cytokine gene expression signature in lung adenocarcinoma
and the surrounding tissue as a prognostic classifier. J Natl
Cancer Inst. 99:1257–1269. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Okamura H, Tsutsi H, Komatsu T, et al:
Cloning of a new cytokine that induces IFN-gamma production by T
cells. Nature. 378:88–91. 1995. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Coughlin CM, Salhany KE, Wysocka M, et al:
Interleukin-12 and interleukin-18 synergistically induce murine
tumor regression which involves inhibition of angiogenesis. J Clin
Invest. 101:1441–1452. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Son YI, Dallal RM, Mailliard RB, Egawa S,
Jonak ZL and Lotze MT: Interleukin-18 (IL-18) synergizes with IL-2
to enhance cytotoxicity, interferon-gamma production, and expansion
of natural killer cells. Cancer Res. 61:884–888. 2001.PubMed/NCBI
|
|
15
|
Park S, Cheon S and Cho D: The dual
effects of interleukin-18 in tumor progression. Cell Mol Immunol.
4:329–335. 2007.PubMed/NCBI
|
|
16
|
Johnson SM, Grosshans H, Shingara J, et
al: Ras is regulated by the let-7 microRNA family. Cell.
120:635–647. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, et al: MicroRNA expression profiles classify human cancers.
Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yanaihara N, Caplen N, Bowman E, et al:
Unique microRNA molecular profiles in lung cancer diagnosis and
prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Seike M, Goto A, Okano T, et al: MiR-21 is
an EGFR-regulated anti-apoptonic factor in lung cancer in
never-smokers. Proc Natl Acad Sci USA. 106:12085–12090. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pass HI, Goparaju C, Ivanov S, et al:
hsa-miR-29c* is linked to the prognosis of malignant pleural
mesothelioma. Cancer Res. 70:1916–1924. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cioce M, Ganci F, Canu V, et al:
Protumorigenic effects of miR-145 loss in malignant pleural
mesothelioma. Oncogene. Nov 18–2013.(Epub ahead of print).
View Article : Google Scholar
|
|
22
|
Shimokawa T, Seike M, Soeno C, et al:
Enzastaurin has anti-tumour effects in lung cancers with
overexpressed JAK pathway molecules. Br J Cancer. 106:867–875.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gemma A, Li C, Sugiyama Y, et al:
Anticancer drug clustering in lung cancer based on gene expression
profiles and sensitivity database. BMC Cancer. 6:1742006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kitamura K, Seike M, Okano T, et al:
MiR-134/487b/655 cluster regulates TGF-β-induced
epithelial-mesenchymal transition and drug resistance to gefitinib
by targeting MAGI2 in lung adenocarcinoma cells. Mol Cancer Ther.
13:444–453. 2014.PubMed/NCBI
|
|
25
|
Thodtmann R, Depenbrock H, Dumez H, et al:
Clinical and pharmacokinetic phase I study of multitargeted
antifolate (LY231514) in combination with cisplatin. J Clin Oncol.
17:3009–3016. 1999.PubMed/NCBI
|
|
26
|
Fakih MG, Pendyala L, Fetterly G, et al: A
phase I, pharmacokinetic and pharmacodynamic study on vorinostat in
combination with 5-fluorouracil, leucovorin, and oxaliplatin in
patients with refractory colorectal cancer. Clin Cancer Res.
15:3189–3195. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Miyanaga A, Gemma A, Noro R, et al:
Antitumor activity of histone deacetylase inhibitors in non-small
cell lung cancer cells: development of a molecular predictive
model. Mol Cancer Ther. 7:1923–1930. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dinarello CA: The paradox of
pro-inflammatory cytokines in cancer. Cancer Metastasis Rev.
25:307–313. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pollari S, Leivonen SK, Perälä M, Fey V,
Käkönen SM and Kallioniemi O: Identification of microRNAs
inhibiting TGF-β-induced IL-11 production in bone metastatic breast
cancer cells. PLoS One. 7:e373612012.
|
|
30
|
Khan S, Brougham CL, Ryan J, et al:
miR-379 regulates cyclin B1 expression and is decreased in breast
cancer. PLoS One. 8:e687532013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yao L, Zhang Y, Chen K, et al: Discovery
of IL-18 as a novel secreted protein contributing to doxorubicin
resistance by comparative secretome analysis of MCF-7 and
MCF-7/Dox. PLoS One. 6:e246842011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Terme M, Ullrich E, Aymeric L, et al:
IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer
Res. 71:5393–5399. 2011. View Article : Google Scholar : PubMed/NCBI
|
